Mantle cell lymphoma recurrent+1
Not recruitingStudy on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine
Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine
- Disease:Mantle cell lymphoma recurrentMantle cell lymphoma refractory
- Substances:Loncastuximab Tesirine
Italy- Participants:18–64 years · 65+ years
- Substances:Loncastuximab Tesirine
- Sponsor:Fondazione Italiana Linfomi Ets











